SCS
BPMC

Syquant Capital SAS’s Blueprint Medicines BPMC Stock Holding History

Syquant Capital SAS’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-805,603
Closed -$103M – 19
2025
Q2 		$103M Buy
+805,603
New +$83.7M 34.24% 1

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Syquant Capital SAS's BPMC Position: Q3 2025 in Review

Syquant Capital SAS sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 805,603 shares — an estimated $103M sold.

Syquant Capital SAS first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $103M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Syquant Capital SAS reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Syquant Capital SAS sold 805,603 Blueprint Medicines shares in Q3 2025, an estimated $103M.
  • Syquant Capital SAS first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
  • Syquant Capital SAS's Blueprint Medicines position peaked at $103M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Syquant Capital SAS's 13F filing for Q3 2025, filed 28 Oct 2025.